118 related articles for article (PubMed ID: 3240729)
1. Hypertensive patients with Raynaud's phenomenon or intermittent claudication and their treatment with ketanserin.
van Oene JC
Drugs; 1988; 36 Suppl 1():148-51. PubMed ID: 3240729
[No Abstract] [Full Text] [Related]
2. Controlled comparison of ketanserin and nifedipine in Raynaud's phenomenon.
Codella O; Caramaschi P; Olivieri O; Perbellini L; Perbellini A; Bambara LM; Corrocher R; De Sandre G
Angiology; 1989 Feb; 40(2):114-21. PubMed ID: 2644876
[TBL] [Abstract][Full Text] [Related]
3. Effect of chronic ketanserin treatment on serotonin-induced platelet aggregation in patients with Raynaud's phenomenon.
Marasini B; Biondi ML; Mollica R
Eur J Clin Pharmacol; 1990; 39(3):289-90. PubMed ID: 2257869
[TBL] [Abstract][Full Text] [Related]
4. Left atrial myxoma presenting with intermittent claudication and Raynaud's phenomenon: echocardiographic patterns of the tumor size.
Kounis NG
Angiology; 1979 May; 30(5):356-60. PubMed ID: 443605
[No Abstract] [Full Text] [Related]
5. Effect of ketanserin on Raynaud's phenomenon in progressive systemic sclerosis: a double-blind trial.
Lukác J; Rovenský J; Tauchmannová H; Zitnan D
Drugs Exp Clin Res; 1985; 11(9):659-63. PubMed ID: 3916837
[TBL] [Abstract][Full Text] [Related]
6. Ketanserin versus nifedipine in secondary Raynaud's phenomenon.
Kirch W; Linder HR; Hutt HJ; Ohnhaus EE; Mahler F
Vasa; 1987; 16(1):77-80. PubMed ID: 3554811
[No Abstract] [Full Text] [Related]
7. Ketanserin treatment and serotonin in patients with primary and secondary Raynaud's phenomenon.
Marasini B; Biondi ML; Bianchi E; Dell'Orto P; Agostoni A
Eur J Clin Pharmacol; 1988; 35(4):419-21. PubMed ID: 3197751
[TBL] [Abstract][Full Text] [Related]
8. [Treatment of Raynaud's phenomenon].
Lazareth I
Ann Dermatol Venereol; 1987; 114(8):1035-8. PubMed ID: 2892456
[No Abstract] [Full Text] [Related]
9. Comparative efficacy of ketanserin and pentoxiphylline in treatment of Raynaud's phenomenon.
Arosio E; Montesi G; Zannoni M; Paluani F; Lechi A
Angiology; 1989 Jul; 40(7):633-8. PubMed ID: 2662829
[TBL] [Abstract][Full Text] [Related]
10. [Treatment of Raynaud's syndrome with ketanserin. Clinical, biological and hemodynamic aspects].
Bellucci S; Kedra AW; Naccache-Herman V; Cambau E; Tobelem G; Caen JP
Presse Med; 1987 Jul 11-18; 16(27):1335. PubMed ID: 2956601
[No Abstract] [Full Text] [Related]
11. New drug therapy in peripheral vascular disease.
Coffman JD
Med Clin North Am; 1988 Jan; 72(1):259-65. PubMed ID: 3276987
[TBL] [Abstract][Full Text] [Related]
12. Ketanserin and capillary flow in Raynaud's phenomenon.
Tooke JE; Williams SA; Rawlinson DW; Black C
Int J Microcirc Clin Exp; 1990 Aug; 9(3):249-55. PubMed ID: 2394546
[TBL] [Abstract][Full Text] [Related]
13. Placebo-controlled trial of ketanserin in the treatment of intermittent claudication.
Cameron HA; Waller PC; Ramsay LE
Angiology; 1987 Jul; 38(7):549-55. PubMed ID: 3304029
[TBL] [Abstract][Full Text] [Related]
14. New prospects for the treatment of Raynaud's phenomenon using a serotoninergic S2 receptor antagonist (ketanserin) and stable derivatives of prostacyclin.
Pola P; Tondi P; Serricchio M; Favuzzi A; Gerardino L
Angiology; 1993 Feb; 44(2):123-8. PubMed ID: 8434805
[TBL] [Abstract][Full Text] [Related]
15. Effect of long-term ketanserin treatment on 5-HT levels, platelet aggregation and peripheral circulation in patients with Raynaud's phenomenon. A double-blind, placebo-controlled cross-over study.
Arneklo-Nobin B; Elmér O; Akesson A
Int Angiol; 1988; 7(1):19-25. PubMed ID: 3290356
[TBL] [Abstract][Full Text] [Related]
16. Does serotonin receptor blockade have a therapeutic effect in Raynaud's phenomenon?
Brouwer RM; Wenting GJ; Visser W; Schalekamp MA
Vasa Suppl; 1987; 18():64-7. PubMed ID: 3299817
[No Abstract] [Full Text] [Related]
17. Therapeutic efficacy of ketanserin, a selective antagonist of the serotonin (5-HT2) receptors, in primary and secondary Raynaud's phenomenon.
Meloni F; Transi MG; Sciacca V; De Felice C; Bagarone A; Sciacca A
Angiology; 1987 Jul; 38(7):530-6. PubMed ID: 3619126
[TBL] [Abstract][Full Text] [Related]
18. Ketanserin in intermittent claudication: effect on walking distance, blood pressure, and cardiovascular complications.
Thulesius O; Lundvall J; Kroese A; Stranden E; Hallböök T; Brunes L; Gjöres JE; Akesson H; Einarsson E; Ohlin P
J Cardiovasc Pharmacol; 1987 Jun; 9(6):728-33. PubMed ID: 2442541
[TBL] [Abstract][Full Text] [Related]
19. Regional intravenous ketanserin and guanethidine therapy in Raynaud's phenomenon.
Caputi CA; De Carolis G; Tomasetti C
Angiology; 1991 Jun; 42(6):473-80. PubMed ID: 2042796
[TBL] [Abstract][Full Text] [Related]
20. [New treatments for Raynaud's syndrome].
Bellucci S; Kedra W; Ajzenberg N; Tobelem G; Caen J
Nouv Rev Fr Hematol (1978); 1988; 30(1-2):103-7. PubMed ID: 3290833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
